Jiangsu Sihuan Bioengineering Co., Ltd (SZSE: 000518)
Health Care · Biotechnology · CN
CN¥3.60
+0.28% today · +51.9% 1Y
Jiangsu Sihuan Bioengineering Co., Ltd (SZSE: 000518) operates in the Biotechnology industry within the Health Care sector. The company is valued at $553.35M and employs 232 people.
Over the last twelve months the share price has gained 51.9%, trading between 2.31 and 4.54.
Tweenvest scores Jiangsu Sihuan Bioengineering Co., Ltd across four factors: quality 65/100, value 47/100, growth 45/100. Its strongest factor is quality.
000518 price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $553.35M
- Revenue (TTM)
- $40.22M
- P/E
- —
- EPS
- -0.05
- Dividend yield
- —
- Beta (5Y)
- 0.30
- 52-week high
- CN¥4.54
- 52-week low
- CN¥2.31
- Avg volume (3M)
- —
- Shares outstanding
- 1.03B
- Employees
- 232
- Next earnings
- —
About Jiangsu Sihuan Bioengineering Co., Ltd
Jiangsu Sihuan Bioengineering Co., Ltd. is a Chinese pharmaceutical company. Its product portfolio includes anti-cancer biotherapeutics such as Drewson, prescribed for renal cancer, malignant melanoma, and cancerous effusions in the chest and abdomen. Another significant oncology drug, Xinde Lusheng, targets a much wider spectrum of malignancies, including kidney, melanoma, lung, gastric, malignant lymphoma, breast, ovarian, bowel, bladder, head and neck tumors, and leukemia, in addition to cancerous pleural effusions. Beyond oncology, the company also produces Xin grain health, a recombinant human granulocyte colony stimulating factor (G-CSF) injection. Additionally, Tourbo, a recombinant human erythropoietin (EPO) injection, addresses anemia stemming from kidney dysfunction in both dialysis-dependent and non-dialysis patients. Established in 1992, Jiangsu Sihuan Bioengineering is headquartered in Jiangyin, China.
- ISIN
- CNE0000001P8
- Founded
- 1992
- Listed since
- Sep 8, 1993
- Exchange
- Shenzhen Stock Exchange
- Currency
- CNY
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Shanghai MicuRx Pharmaceutical Co., Ltd.SHSE: 688373 | $561.38M | CN¥5.73 | -0.87% |
| Zhejiang Orient Gene Biotech Co., LtdSHSE: 688298 | $557.20M | CN¥19.50 | +0.67% |
| DBV Technologies S.A.ENXTPA: DBV | $555.98M | €1.68 | -11.87% |
| Jacobio Pharmaceuticals Group Co., Ltd.SEHK: 1167 | $555.24M | HK$5.57 | -7.40% |
| Thalys Medical Technology Group CorporationSHSE: 603716 | $545.42M | CN¥16.47 | -0.90% |
| TransThera Sciences (Nanjing), Inc.SEHK: 2617 | $541.29M | HK$10.43 | -2.71% |
| Valneva SEENXTPA: VLA | $537.87M | €2.53 | +0.08% |
| Bright Minds Biosciences Inc.CNSX: DRUG | $533.01M | CA$77.10 | +9.22% |
Figures last refreshed Oct 11, 2026.